Sunshine and rash: Testing the role of sunscreen to prevent epidermal growth factor receptor inhibitor-induced rash

Supportive Cancer Therapy

Volumn 4, Issue 4, 2007, Pages 198-202

  Jatoi, Aminah ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Prevention; Squamous cell carcinoma; Ultraviolet light

Indexed keywords

CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; RETINOIC ACID; SUNSCREEN; TETRACYCLINE;

CLINICAL TRIAL; FOLLICULITIS; HUMAN; RASH; REVIEW; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

EID: 35348967015     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.015     Document Type: Review

References (24)

1. Baselga J, Rjschin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of Zd1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292-4302.
2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21:2237-2246.
3. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21:1980-1987.
4. Herbst RS, Maddox A, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-3825.
5. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
6. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003; 17:23-28.
7. Jatoi A, Rowland K, Sloan J, et al. Does tetracycline prevent or palliate epidermal growth factor receptor inhibitor-induced rash? Results of a phase III trial from the North Central Cancer Treatment Group. J Clin Oncol 2007; 25(18 suppl):494s (Abstract #LBA9006).
8. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2001; 20:110-124.
9. van Doorn R, Kirtschig G, Scheffer E, et al. Follicular and epidermal alterations in patients treated with ZD1839, an inhibitor of the epidermal growth factor receptor. Br J Dermatology 2002; 147:598-601.
10. Luu M, Lai SE, Patel J, et al. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed 2007; 23:42-45.
11. Bender K, Blattner C, Knebel A, et al. UV-induced signal transduction. J Photochem Photobiol B 1997; 37:1-17.
12. Huang RP, Wu JX, Fan Y, et al. UV activates growth factor receptors via reactive oxygen intermediates. J Cell Biol 1996; 133:211-220.
13. Sachsenmaier C, Radler-Pohl A, Zinck R, et al. Involvement of growth factor receptors in the mammalian UVC response. Cell 1994; 78:963-972.
14. Lewis D, Zweig B, Hurwitz SA, et al. Inhibition of erbB receptor family members protects HaCaT keratinocytes from ultraviolet-B-induced apoptosis. J Invest Dermatol 2003; 120:483-488.
15. Jost M, Huggett TM, Kari C, et al. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-XL expression through a MEK-dependent pathway. J Biol Chem 2001; 276:6320-6326.
16. Peus D, Vasa RA, Meves A, et al. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem Photobiol 2000; 72:135-140.
17. El-Abaseri TB, Fuhrman J, Trempus C, et al. Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res 2005; 65:3958-3965.
18. Diffey B. Has the sun protection factor had its day? BMJ 2000; 320:176-177.
19. Kullavanijaya P, Lim HW. Photoprotection. J Am Acad Dermatol 2005; 52:937-958.
20. Green A, Williams G, Neale R, et al. Daily sunscreen application and betacarotene supplementation in prevention of basal-cell and squamous cell carcinomas of the skin: a randomized controlled trial. Lancet 1999; 354:723-729.
21. Naylor MF, Boyd A, Smith DW. High sun protection sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995; 131:170-175.
22. Marks R, Foley PA, Jolley D, et al. The effect of regular sunscreen use on vitamin D levels in an Australian population: results of a randomized controlled trial. Arch Dermatol 1995; 131:415-421.
23. Farrerons J, Barnadas M, Lopez-Navidad A, et al. Sunscreen and risk of osteoporosis in the elderly: a two-year follow-up. Dermatology 2001; 202:27-30.
24. Scientific Committee on Cosmetic Products and Non-Food Products. Opinion of the scientific committee on cosmetic products of non-food products intended for consumers concerning 3-(4′-Methylbenzylidene)-D, L-Camphor. Adopted by the plenary session of the SCCNFP of 21 January 1998. Brussels: Scientific Committee on Cosmetic Products and Non-Food Products, 1998.